Last $4.91 USD
Change Today -0.04 / -0.81%
Volume 128.0K
NEO On Other Exchanges
As of 5:20 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

neogenomics inc (NEO) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/10/14 - $6.10
52 Week Low
04/15/14 - $2.95
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEOGENOMICS INC (NEO)

Related News

No related news articles were found.

neogenomics inc (NEO) Related Businessweek News

No Related Businessweek News Found

neogenomics inc (NEO) Details

NeoGenomics, Inc., together with its subsidiary, NeoGenomics Laboratories, Inc., operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company performs analyses for hematopoietic cancers, such as leukemia and lymphoma; and solid tumor cancers comprising breast, lung, colon, and bladder cancer. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry testing services to identify cell proteins in a tissue section; and molecular testing services that focus on the analysis of DNA and RNA, as well as on the structure and function of genes at the molecular level. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

315 Employees
Last Reported Date: 05/8/14
Founded in 2001

neogenomics inc (NEO) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $557.0K
Chief Financial Officer
Total Annual Compensation: $305.5K
Chief Medical Officer and Director of Researc...
Total Annual Compensation: $92.5K
Chief Compliance Officer, Executive Vice Pres...
Total Annual Compensation: $72.5K
Compensation as of Fiscal Year 2013.

neogenomics inc (NEO) Key Developments

NeoGenomics, Inc. Launches New Tests for the Detection of Mutations in the Bruton tyrosine kinase and PLC-gama2 Genes

NeoGenomics Inc. announced that it has launched new tests for the detection of mutations in the Bruton tyrosine kinase (BTK) and PLC-gama2 genes for predicting acquired resistance to BTK inhibitors. In addition, NeoGenomics launched a lymphoma profiling test specifically to predict susceptibility to BTK inhibitors and test for mutations in CXCR4, CD79B, MYD88, and CARD11 genes in various types of lymphoma. BTK inhibitors are highly effective in the treatment of patients with chronic lymphocytic leukemia (CLL) and certain subtypes of lymphoma, including mantle cell lymphoma and diffuse large B-cell lymphoma (DLBCL). However, some patients develop resistance to BTK inhibitors while on therapy. Mutations in BTK and PLC-gama2 genes were found to be responsible for this resistance. Demonstration of the presence of these mutations confirms the resistance and guides physicians to switch to more effective therapy.

Neogenomics Inc. Announces Amendments to Articles of Incorporation or Bylaws

On October 14, 2014, the Board of Neogenomics Inc. determined that it was in the best interests of the Company and its stockholders to amend and restate the company’s Bylaws, and approved and adopted the amended and restated Bylaws of the Company. The amended and restated Bylaws became effective immediately upon their adoption.

NeoGenomics, Inc. Launches 315 Gene Next Generation Sequencing Test for Solid Tumor Discovery Profiling

NeoGenomics Inc. announced the addition of a new comprehensive solid tumor profiling test designed for clinical discovery and to support clinical trials. The test utilizes next generation sequencing (NGS) to analyze variants in the coding sequence of 315 genes and uses conventional Fluorescent in Situ Hybridization (FISH) methods to identify large deletions, amplifications and translocations in 9 different chromosomal loci. This multimodality cancer profiling test is unique and will address some of the limitations of NGS when used in a stand-alone fashion. It will not only detect the common molecular abnormalities in specific cancers, but may also discover unexpected abnormalities that could open up new therapeutic options for physicians and their patients.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEO:US $4.91 USD -0.04

NEO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Reference Laboratories Inc $29.33 USD +0.08
Foundation Medicine Inc $24.71 USD +1.71
Genomic Health Inc $33.65 USD +0.57
Response Genetics Inc $0.63 USD -0.024
Rosetta Genomics Ltd $3.02 USD +0.11
View Industry Companies

Industry Analysis


Industry Average

Valuation NEO Industry Range
Price/Earnings 100.0x
Price/Sales 3.3x
Price/Book 10.7x
Price/Cash Flow 134.7x
TEV/Sales 3.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOGENOMICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at